{"id":"raloxifen","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Hot flashes","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Leg cramps","drugRate":"7.1%","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Flu syndrome","drugRate":"","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Sweating","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Atrial fibrillation","Breastfeeding (mother)","Cardiovascular event risk","Cerebrovascular accident","Chronic heart failure","Deep venous thrombosis","Disease of liver","Disorder of coronary artery","Hypertensive disorder","Hypertriglyceridemia","Impaired renal function disorder","Lupus anticoagulant disorder","Pregnancy, function","Pulmonary thromboembolism","Smokes tobacco daily","Thrombophilia","Thrombophlebitis","Thrombosis of retinal vein","Transient ischemic attack"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Venous thromboembolism (deep venous thrombosis, pulmonary embolism, retinal vein thrombosis)","drugRate":"1%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1079109","moleculeType":"Small molecule","molecularWeight":"459.57"},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"6f7eb934-aa60-51e1-e053-2a91aa0a3914","title":"RALOXIFENE HYDROCHLORIDE TABLET, FILM COATED [AVPAK]"},"ecosystem":[],"mechanism":{"target":"Aldehyde oxidase, HLA class I histocompatibility antigen, A-3 alpha chain, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase"},"_scrapedAt":"2026-03-28T00:03:38.180Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Postmenopausal osteoporosis","diseaseId":"postmenopausal-osteoporosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Breast Carcinoma","diseaseId":"prevention-of-breast-carcinoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00431431","phase":"PHASE4","title":"Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-07-31","conditions":"Osteopenia","enrollment":324},{"nctId":"NCT01573637","phase":"PHASE3","title":"Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women","status":"COMPLETED","sponsor":"Fundació Sant Joan de Déu","startDate":"2011-07","conditions":"Schizophrenia in Post Menopausal Women","enrollment":78},{"nctId":"NCT05386784","phase":"PHASE4","title":"Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2020-12-16","conditions":"Postemenopusal Women With Osteopenia","enrollment":112},{"nctId":"NCT03010267","phase":"PHASE1","title":"DP-R213 Phase 1 Pharmacokinetics Study","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2017-01-03","conditions":"Healthy","enrollment":46},{"nctId":"NCT02762643","phase":"PHASE1","title":"DP-R213 Pharmacokinetics Study","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2016-05","conditions":"Healthy","enrollment":61}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"COUGH"},{"count":3,"reaction":"PNEUMONIA"},{"count":2,"reaction":"ASTHMA"},{"count":2,"reaction":"BRADYCARDIA"},{"count":2,"reaction":"DIZZINESS"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"HEADACHE"},{"count":2,"reaction":"MUSCLE SPASMS"},{"count":2,"reaction":"MYOCARDIAL INFARCTION"},{"count":2,"reaction":"NAUSEA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":103,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"raloxifen","genericName":"raloxifen","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}